Alaunos Therapeutics, Inc. quarterly report, Q2 FY2011

Documento completo

Filing identity and reporting period

Important metadata discrepancy: The supplied filing is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2011—not a filing for Alaunos Therapeutics, Inc. Investors should verify the issuer and filing before relying on this summary. ZIOPHARM described itself as a development-stage biopharmaceutical company focused on oncology drug development.

Financial results and liquidity

Unless otherwise noted, amounts are in U.S. dollars.

  • Revenue: Q2 2011 research contract revenue was $0.2 million; six-month revenue was $0.267 million, versus none in the comparable 2010 periods. Revenue was recognized over the estimated performance period for the darinaparsin collaboration.
  • Operating expenses and loss: Q2 operating expenses were $13.0 million and operating loss was $12.8 million, compared with $5.1 million of expenses and operating loss in Q2 2010. For the first six months, operating expenses were $41.0 million and operating loss was $40.8 million, versus $9.7 million and $9.7 million, respectively, in 2010.
  • Net income (loss): Q2 2011 net loss was $10.7 million, or $0.16 per basic and diluted share, versus net income of $9.0 million, or $0.21 basic and $0.19 diluted per share, in Q2 2010. Six-month net loss was $49.7 million, or $0.78 per share, versus a $8.6 million loss, or $0.21 per share, in 2010. Results were materially affected by noncash changes in warrant fair value.
  • Cash flow: Six-month operating cash use was $14.0 million, compared with $8.1 million in 2010; investing cash use was $0.4 million. Financing provided $84.3 million, including $71.2 million of net proceeds from stock and warrant issuances. Cash increased by $69.9 million to $130.3 million.
  • Liquidity and liabilities: Current assets were $131.3 million and current liabilities $8.7 million, yielding reported working capital of $122.6 million. Total liabilities were $48.7 million, including a $36.0 million warrant liability. The filing reports no conventional borrowings or interest paid.
  • Equity and dilution: Common shares outstanding rose to 68.3 million at June 30 from 48.5 million at December 31, 2010. The company reported 13.3 million warrants outstanding at quarter-end. A further 3.6 million shares could be issued to Intrexon upon specified clinical-trial dosing conditions.
  • Margins: The company had minimal collaboration revenue and reported operating losses; the filing does not present a meaningful commercial gross margin.

Material changes versus the prior comparable period

  • Six-month R&D expense rose $29.6 million to $33.8 million. The increase included a one-time, noncash $17.5 million charge for in-process R&D related to the Intrexon arrangement, as well as higher palifosfamide and DNA-therapeutics clinical costs, manufacturing activity, and personnel costs.
  • Six-month G&A expense increased 32% to $7.3 million, primarily reflecting higher consulting, personnel, and travel costs.
  • The six-month warrant fair-value movement changed from a $1.0 million gain in 2010 to an $9.0 million loss in 2011. In Q2, it was a $2.1 million gain in 2011 versus a $14.1 million gain in 2010; these noncash valuation changes significantly affected reported net income.
  • Cash rose substantially following the February 2011 public offering and Intrexon-related stock transactions. In January, Intrexon purchased shares for $11.6 million and received additional shares for nominal cash consideration, producing the $17.5 million noncash R&D charge.

Outlook, risks, and unusual items

  • Management believed available cash would fund operations into early 2013, but expected further financing would be needed for longer-term clinical trials and product development. Apart from a conditional Intrexon purchase commitment, the company reported no committed additional capital source.
  • For the next 12 months, management forecast approximately $73.8 million in R&D expense and $15.7 million in G&A expense. The filing cautions that actual costs and cash runway could differ materially, particularly as Intrexon-related programs expand.
  • Key programs included the Phase 3 PICASSO 3 palifosfamide trial, oral darinaparsin studies, indibulin development, and Intrexon-partnered DNA therapeutics. Management disclosed slower-than-expected PICASSO 3 enrollment, regulatory-site delays, limited availability of doxorubicin, and a target of full enrollment by year-end 2011 that the company could not assure.
  • The filing described clinical, regulatory, manufacturing, intellectual-property, competition, reimbursement, and financing risks. No product candidate had been approved for commercial sale, and the company expected continuing losses.
  • The Solasia agreement granted pan-Asian/Pacific rights to darinaparsin. It included a $5.0 million upfront payment, up to $32.5 million in development milestones, up to $53.5 million in sales milestones, and potential double-digit royalties and sublicense revenue participation; milestone and royalty amounts were contingent, not assured.
  • Subsequent events: the company signed a New York headquarters lease extending to January 2019, with approximately $2.9 million in total payments, and extended the Harmon Hill agreement through April 8, 2012. At June 30, contractual obligations totaled $19.2 million, including $14.2 million in contract milestones, largely dependent on future events.
  • Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. Legal proceedings were reported as not applicable.

Most important facts for investors to verify

  1. Confirm that the intended filing is ZIOPHARM’s 2011 Q2 10-Q; the request metadata names a different company.
  2. Assess whether the early-2013 cash runway remains credible against the forecast spending, clinical-trial enrollment and cost risks, and financing needs.
  3. Review PICASSO 3 enrollment progress and the clinical, regulatory, and supply risks affecting the palifosfamide program.
  4. Distinguish operating performance and cash burn from noncash warrant remeasurement and the $17.5 million Intrexon-related charge.
  5. Evaluate potential dilution from outstanding warrants, equity financing, and the conditional Intrexon share issuance, alongside the terms and conditions of Intrexon’s remaining purchase commitment.
  6. Verify the status and economics of contingent collaboration milestones, royalties, and contractual obligations, including the post-quarter lease.